Immunic, Inc. (NASDAQ:IMUX) Receives Consensus Rating of “Buy” from Analysts

Shares of Immunic, Inc. (NASDAQ:IMUX) have received a consensus rating of “Buy” from the eight brokerages that are presently covering the firm, MarketBeat Ratings reports. Six equities research analysts have rated the stock with a buy recommendation and two have given a strong buy recommendation to the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $12.67.

A number of analysts have issued reports on IMUX shares. D. Boral Capital reiterated a “buy” rating and set a $17.00 price target on shares of Immunic in a research note on Wednesday, February 26th. StockNews.com lowered shares of Immunic from a “hold” rating to a “sell” rating in a research note on Saturday, February 22nd. Finally, HC Wainwright reiterated a “buy” rating and set a $10.00 price target on shares of Immunic in a research note on Friday, February 21st.

Immunic Price Performance

Shares of NASDAQ:IMUX opened at $1.15 on Monday. The firm has a market capitalization of $103.59 million, a PE ratio of -0.93 and a beta of 1.89. The firm’s 50-day moving average is $1.05 and its two-hundred day moving average is $1.24. Immunic has a 1 year low of $0.92 and a 1 year high of $2.11.

Institutional Trading of Immunic

Large investors have recently made changes to their positions in the company. Virtu Financial LLC purchased a new stake in shares of Immunic during the third quarter worth approximately $50,000. Invesco Ltd. acquired a new position in Immunic in the fourth quarter valued at approximately $37,000. Jane Street Group LLC boosted its holdings in Immunic by 121.4% in the third quarter. Jane Street Group LLC now owns 70,299 shares of the company’s stock valued at $116,000 after purchasing an additional 38,553 shares in the last quarter. HB Wealth Management LLC acquired a new position in Immunic in the fourth quarter valued at approximately $81,000. Finally, Barclays PLC acquired a new position in Immunic in the fourth quarter valued at approximately $84,000. 51.82% of the stock is currently owned by hedge funds and other institutional investors.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.